60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
60 Degrees Pharmaceuticals's gross margin for the twelve months ending Jun 30, 2026 was 19.4%. For fiscal 2025 it was 22.3%, against 36.7% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22.3% | −14.4 |
| FY2024 | Dec 31, 2024 | 36.7% | +123.8 |
| FY2023 | Dec 31, 2023 | -87.1% | +6.6 |
| FY2022 | Dec 31, 2022 | -93.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 27.3% | −23.1 |
| Q1 FY2026 | Mar 31, 2026 | 47.1% | −8.1 |
| Q4 FY2025 | Dec 31, 2025 | 60.2% | +9.1 |
| Q3 FY2025 | Sep 30, 2025 | -22.9% | −40.3 |
| Q2 FY2025 | Jun 30, 2025 | 50.4% | +22.1 |
| Q1 FY2025 | Mar 31, 2025 | 55.2% | +17.1 |
| Q4 FY2024 | Dec 31, 2024 | 51.1% | +67.5 |
| Q3 FY2024 | Sep 30, 2024 | 17.4% | +56.5 |
| Q2 FY2024 | Jun 30, 2024 | 28.3% | +237.4 |
| Q1 FY2024 | Mar 31, 2024 | 38.1% | +363.9 |
| Q4 FY2023 | Dec 31, 2023 | -16.4% | −61.5 |
| Q3 FY2023 | Sep 30, 2023 | -39.1% | +53.8 |
| Q2 FY2023 | Jun 30, 2023 | -209.0% | – |
| Q1 FY2023 | Mar 31, 2023 | -325.8% | – |
| Q3 FY2022 | Sep 30, 2022 | 45.1% | – |
| Q2 FY2022 | Jun 30, 2022 | -92.9% | – |